St. Jude Medical Release: Data Shows The CardioMEMS HF System Significantly Reduced 30-Day Hospital Readmission Rates
ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced a retrospective data analysis from the CHAMPION clinical trial showing significant a reduction in 30-day hospital readmission rates for patients age 65 and older. The CHAMPION trial looked at the safety and effectiveness of the CardioMEMS™ HF System for patients with New York Heart Association (NYHA) Class III heart failure (HF) who had been hospitalized for HF in the previous 12 months. The analysis — Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalization and All-Cause 30-Day Readmissions in Medicare-Eligible patients with NYHA Class III Heart Failure — was presented during the American Heart Association Scientific Sessions.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.